• Publications
  • Influence
Characterisation of the effects of nicotine in the five-choice serial reaction time task in rats: antagonist studies
The results demonstrate that the α7 receptor subtype is not involved in the effects of nicotine in the 5-CSRTT and that its effects are more likely to be mediated by a receptor(s) such as α4β2, α4 β4 and/or α3β2 which is sensitive to antagonism by dihydro-β-erythroidine. Expand
Differences in anxiety-related behaviours and in sensitivity to diazepam in inbred and outbred strains of mice
The finding of differential strain distributions both with and without diazepam treatment in the light/dark and the elevated plus-maze tests, indicates that not all strains of mice are suitable for investigating the effects of GABA/BZ receptor ligands. Expand
A Comparative Study of the Effects of Selective and Non-Selective 5-HT2 Receptor Subtype Antagonists in Rat and Mouse Models of Anxiety
The behavioural profiles suggest that blockade of the 5-HT2A receptor may not reduce anxiety and demonstrate that 5-ht2B and/or 5- HT2C receptor subtypes may be primarily involved in the anxiolytic-like effects of mianserin and SB 206553 in rats. Expand
Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects.
The highly selective sedative effect of zolpidem (as compared to myorelaxant and anticonvulsant effects) suggests that it may possess a specificity for certain subtypes of benzodiazepine receptors. Expand
Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents Comparison with diazepam and buspirone
Although in mice the anxiety-reducing potential of CP-154,526 is superior to that of the atypical anxiolytic buspirone, it is smaller in terms of the magnitude of the effects and the number of indices of anxiety affected than that of diazepam. Expand
Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
This pharmacological profile of amisulpride, characterized by a preferential blockade of effects involving presynaptic mechanisms and limbic structures, may explain the clinical efficacy of this drug against both negative and positive symptoms of schizophrenia and its low propensity to produce extrapyramidal side effects. Expand
The Pharmacology and Mechanisms of Action of New Generation, Non-Benzodiazepine Hypnotic Agents
  • D. Sanger
  • Chemistry, Medicine
  • CNS Drugs
  • 1 November 2004
The new generation hypnotic drugs, zolpidem, zopiclone and zaleplon, are at least as efficacious in the clinic as benzodiazepines and may offer advantages in terms of safety, according to recent studies using genetically modified mice. Expand
Comparison of the pharmacological profiles of the hypnotic drugs, zaleplon and zolpidem.
The results show that zaleplon and zolpidem have similar pharmacological profiles, presumably related to their BZ1 (omega 1) receptor selectivity, however, the difference between doses producing motor deficits and those giving rise to other effects was greater for zolPidem than for zalplon. Expand
Evidence for the involvement of dopamine receptors in ethanol-induced hyperactivity in mice
The results indicate that activation of D1 and D2/D3 DA receptors is implicated in ethanol-induced hyperactivity whereas other mechanisms might mediate the sedative effects of ethanol. Expand
Risk Assessment Behaviour: Evaluation of Utility in the Study of 5-HT-Related Drugs in the Rat Elevated Plus-Maze Test
It is demonstrated that risk assessment responses are sensitive to the action of 5-HT1A receptor ligands, but their modulation by drugs targetting 5- HT2A,5-HT2C, and 4-HT3 receptors was not convincingly established. Expand